Mark Tebbe

Mark co-founded Quench Bio with Atlas Venture and Arix Bioscience where he is the Chief Technology Officer. He is also an Atlas EIR. Formerly, Mark was VP and Head of Drug Discovery at Quartet Medicine. Mark has >24 years of experience in drug discovery and development and is a co-inventor of Incivek ™ (Telaprevir), an HCV protease inhibitor. Before Quartet, he was VP of Medicinal and Computational Chemistry at Forma Therapeutics where he focused on small molecule cancer therapeutics. Prior to that, Mark worked with Eli Lilly over a 16-year career as head of chemistry in Hamburg, Germany, and Research Triangle Park, North Carolina as well as Global Head of Operations for the discovery chemistry group. He obtained his Ph. D. in organic chemistry from Stanford University and his undergraduate degree from the University of Notre Dame.